Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Am J Physiol Renal Physiol. 2010 May;298(5):F1067-77. doi: 10.1152/ajprenal.00005.2010. Epub 2010 Feb 24.
The ultrasensitive energy sensor AMP-activated protein kinase (AMPK) orchestrates the regulation of energy-generating and energy-consuming pathways. AMPK is highly expressed in the kidney where it is reported to be involved in a variety of physiological and pathological processes including ion transport, podocyte function, and diabetic renal hypertrophy. Sodium transport is the major energy-consuming process in the kidney, and AMPK has been proposed to contribute to the coupling of ion transport with cellular energy metabolism. Specifically, AMPK has been identified as a regulator of several ion transporters of significance in renal physiology, including the cystic fibrosis transmembrane conductance regulator (CFTR), the epithelial sodium channel (ENaC), the Na(+)-K(+)-2Cl(-) cotransporter (NKCC), and the vacuolar H(+)-ATPase (V-ATPase). Identified regulators of AMPK in the kidney include dietary salt, diabetes, adiponectin, and ischemia. Activation of AMPK in response to adiponectin is described in podocytes, where it reduces albuminuria, and in tubular cells, where it reduces glycogen accumulation. Reduced AMPK activity in the diabetic kidney is associated with renal accumulation of triglyceride and glycogen and the pathogenesis of diabetic renal hypertrophy. Acute renal ischemia causes a rapid and powerful activation of AMPK, but the functional significance of this observation remains unclear. Despite the recent advances, there remain significant gaps in the present understanding of both the upstream regulating pathways and the downstream substrates for AMPK in the kidney. A more complete understanding of the AMPK pathway in the kidney offers potential for improved therapies for several renal diseases including diabetic nephropathy, polycystic kidney disease, and ischemia-reperfusion injury.
超敏能量传感器 AMP 激活的蛋白激酶(AMPK)协调能量产生和消耗途径的调节。AMPK 在肾脏中高表达,据报道,它参与多种生理和病理过程,包括离子转运、足细胞功能和糖尿病肾肥大。钠转运是肾脏的主要能量消耗过程,AMPK 被认为有助于离子转运与细胞能量代谢的偶联。具体而言,AMPK 已被确定为几种在肾脏生理学中具有重要意义的离子转运体的调节剂,包括囊性纤维化跨膜电导调节剂(CFTR)、上皮钠通道(ENaC)、Na(+)-K(+)-2Cl(-)共转运体(NKCC)和液泡 H(+)-ATP 酶(V-ATPase)。肾脏中 AMPK 的鉴定调节剂包括膳食盐、糖尿病、脂联素和缺血。在足细胞中,脂联素激活 AMPK 可减少白蛋白尿,在肾小管细胞中,脂联素激活 AMPK 可减少糖原积累。糖尿病肾脏中 AMPK 活性降低与甘油三酯和糖原在肾脏中的积累以及糖尿病肾肥大的发病机制有关。急性肾缺血导致 AMPK 的快速和强大激活,但这一观察结果的功能意义尚不清楚。尽管最近取得了进展,但对肾脏中 AMPK 的上游调节途径和下游底物的理解仍存在重大差距。对肾脏中 AMPK 途径的更全面了解为几种肾脏疾病(包括糖尿病肾病、多囊肾病和缺血再灌注损伤)的治疗提供了潜在的改善。